ret

(redirected from Receptor tyrosine kinase)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

ret

[ret]
(chemistry)
The reduction or digestion of fibers (usually linen) by enzymes.

RET.

On drawings, abbr. for return.
References in periodicals archive ?
TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53
TABLE 79 ASIAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($
Summary: TEHRAN (FNA)- Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene.
ARQ 197 mediates its effects by inhibiting the activity of c-Met, a receptor tyrosine kinase that plays multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis.
Receptor tyrosine kinases have been widely implicated in the generation and progression of common human tumors, including HNSCC.
The poster entitled "BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase Axl, enhances immune checkpoint inhibitor efficacy", was presented on Friday, September 18.
The European Medicines Agency (EMA) has approved Eisai's request for accelerated assessment of the investigational oral multiple receptor tyrosine kinase (RTK) inhibitor lenvatinib, for the treatment of patients with progressive radioiodine-refractory, differentiated thyroid cancer (RR-DTC).
The signal transduction pathway involves an interaction between a MDK1 receptor tyrosine kinase and a receptor for the kinase.
Mutations in the KIT receptor tyrosine kinase give rise to the critical transforming oncoprotein in 85% of gastrointestinal stromal tumors (GISTs).
BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 - June 2, 2015.
A second study will investigate Opdivo with INC280, a potent and highly selective inhibitor of c-MET receptor tyrosine kinase, and separately with EGF816, a potent, third-generation EGFR tyrosine kinase inhibitor that is active against T790 mutations.
Tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kinase, is being evaluated for the treatment of patients diagnosed with hepatocellular carcinoma (HCC) who have received one or two prior systemic anti-cancer therapies.

Full browser ?